1. Core M&A Transaction Steps and Key Milestones
| Transaction Phase | Primary Legal Objective | Common Risk |
|---|---|---|
| Due Diligence | Identify material liabilities and regulatory status | Incomplete disclosure or hidden litigation |
| Definitive Agreement | Allocate risk through representations and warranties | Misaligned expectations on survival periods |
| Regulatory Approvals | Obtain antitrust clearance and industry permits | Unexpected regulatory objections |
| Closing | Verify conditions satisfied and fund purchase price | Breach of closing condition or financing failure |
Each phase requires counsel to assess whether the transaction will proceed and what legal risks remain unresolved. Due diligence is the foundation, because counsel must gather enough factual information to advise the buyer on the true financial and legal state of the target company, and to advise the seller on what representations it can safely make without facing post-closing indemnification claims.
2. Due Diligence and Information Gathering
Due diligence succeeds based on whether counsel has identified all material contracts, pending litigation, regulatory compliance gaps, and third-party consents required for the deal to close. A buyer's counsel must review corporate records, tax filings, employment agreements, customer and supplier contracts, intellectual property registrations, and environmental reports to determine whether the target's business is sustainable post-acquisition and whether hidden liabilities will drain value after closing.
Counsel should focus on contract review provisions that require consent upon change of control, because these clauses can block the transaction or force renegotiation of key commercial terms. Seller's counsel must also conduct a thorough review to understand what representations and warranties the buyer will demand and to assess the seller's exposure to indemnification claims after closing.
A common procedural pitfall arises when counsel delays or incompletely documents diligence findings. Counsel should maintain a detailed diligence memo, including a schedule of all exceptions to representations and warranties, so that the buyer and seller have a clear record of what was disclosed and what was not.
3. Representations, Warranties, and Indemnification Allocation
The purchase agreement allocates risk between buyer and seller through representations, warranties, and indemnification provisions. Representations and warranties are factual assertions about the target company's business, financial condition, and legal compliance; indemnification clauses specify which party will pay for losses if a representation or warranty proves false after closing.
Counsel must negotiate survival periods, the time after closing during which a party can bring an indemnification claim, and basket thresholds, the minimum amount of losses before indemnification applies. A buyer often seeks extended survival periods for fundamental representations like title and capitalization, and shorter periods for operational representations. Sellers resist long survival periods because they create years of contingent liability and complicate the seller's ability to exit the deal cleanly.
Escrow holdbacks are a practical mechanism to secure indemnification obligations. Counsel should ensure that the escrow agreement clearly defines claim procedures, the claims agent's role, and the timeline for fund release. Disputes over escrow release can be costly, so counsel should anticipate these risks in the initial agreement structure.
4. Regulatory Approval and Industry-Specific Considerations
Many M&A transactions require regulatory approval from federal or state agencies, and counsel must identify these requirements early to avoid deal delay or failure. Antitrust review under the Hart-Scott-Rodino Act applies to transactions above a specified size threshold; healthcare transactions may require review by state attorneys general and the Federal Trade Commission.
Counsel advising on hospital mergers and acquisitions must navigate Certificate of Need laws in many states, which require prior approval before a hospital can acquire another facility or expand services. Similarly, counsel advising on pharmacy mergers and acquisitions must ensure compliance with state pharmacy board rules, DEA controlled-substance transfer requirements, and insurance network adequacy standards that may be triggered by a change of ownership.
Counsel should also review whether the transaction triggers third-party consent requirements in material contracts. Failure to obtain required consents can result in contract termination or breach liability post-closing, so counsel should prioritize consent solicitation during the definitive agreement phase.
5. New York M&A Practice and Closing Procedures
New York courts have developed well-established procedural frameworks for resolving disputes over purchase agreement interpretation, indemnification claims, and closing condition satisfaction. When disputes arise, counsel must be prepared to present evidence of the parties' intent through the purchase agreement text, negotiation history, and pre-closing communications.
A procedural risk in New York practice is that parties sometimes fail to create a clear written record of closing condition satisfaction or waiver at or before closing. If a party later claims that a closing condition was not satisfied, the absence of contemporaneous written documentation can complicate the party's ability to establish waiver or estoppel. Counsel should ensure that closing deliverables include a closing certificate confirming that all closing conditions have been satisfied or waived in writing.
Post-closing disputes over indemnification claims are common in New York commercial practice. A buyer's indemnification claim must be supported by detailed evidence showing the nature of the loss, the causal link to a breach of representation or warranty, and the amount of damages. Counsel should advise the buyer to preserve all documents related to the claim to create a complete evidentiary record if the dispute escalates to litigation or arbitration.
6. Strategic Documentation and Protective Measures
Counsel should implement a documentation protocol throughout the M&A process to protect both parties and reduce post-closing dispute risk. A deal timeline that tracks key milestones, approval deadlines, and closing conditions helps counsel identify potential delays early and communicate with all stakeholders about progress and risks.
Counsel should also maintain a detailed record of all diligence findings, regulatory submissions, consent solicitations, and closing deliverables. This documentation becomes critical if a dispute arises post-closing, because it establishes what information was available to the parties and what closing conditions were satisfied. In many cases, a well-organized deal file can resolve a dispute without litigation by demonstrating to both parties what actually occurred.
Before closing, counsel should conduct a final compliance review to confirm that all regulatory approvals have been obtained, all material consents have been secured, and all closing conditions have been satisfied or waived in writing. This final step prevents closing delays and reduces the risk of post-closing disputes over whether the transaction actually closed on the agreed terms.
26 May, 2026









